Yes, it's uncanny how confident the shorters are to keep adding...

Yes, it's uncanny how confident the shorters are to keep adding fake shares to keep the price under control. Not long ago Clinuvel started a Phase 3 trial into blockbuster Vitiligo - and this is just as a new indication to an already FDA, EMA APPROVED and safe drug. Clinuvel is already extremely profitable and growing - so much so that they are financially comparable only to very few biotechs one of which is PME which is valued a whopping more than 12 times greater. And look how close they are on financials below and IMO with Vitiligo approval CUV would easily surpass those PME figures. So do shorters think Vitiligo will not get approval despite great Phase 2 results? They did bet big against EPP FDA approval which was much harder to prove due to being the first indication for this drug and harder to show data for, yet they were wrong about that.

Pro Medicus FY2023 Revenue $125 Million, Profit after tax $60.6Million. Market cap $10.5 Billion. (p/e ~ 170)
Clinuvel, FY2023 Revenue $78 Million, Profit after tax $30.6Million. Market cap $0.8 Billion. (p/e ~ 22)

I like how the Chair at Polynovo led the fight against the shorters by personally buying millions of shares on market. Fake shares pushed the price down to stupid low $1 levels and in a pretty short time the share price has come back nicely. No fear of mentioning shorters from DW and despite being a bigger company than CUV he was not shy about leaving a direct mobile phone number for communication and responding to texts. What a champion (I really think Prof. Rosenfeld should book a lunch meeting with this guy).

All IMO DYOR